NANOPHASE TECHNOLOGIES Corp (NASDAQ:SLSN - Get Free Report) COO Kevin Cureton sold 38,807 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $3.80, for a total transaction of $147,466.60. Following the completion of the transaction, the chief operating officer now owns 192,212 shares in the company, valued at $730,405.60. The trade was a 16.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Kevin Cureton also recently made the following trade(s):
- On Thursday, June 5th, Kevin Cureton sold 4,693 shares of NANOPHASE TECHNOLOGIES stock. The stock was sold at an average price of $3.96, for a total value of $18,584.28.
NANOPHASE TECHNOLOGIES Stock Up 3.9%
SLSN stock traded up $0.15 during mid-day trading on Monday, hitting $3.99. The company had a trading volume of 123,322 shares, compared to its average volume of 91,884. NANOPHASE TECHNOLOGIES Corp has a 12-month low of $1.21 and a 12-month high of $16.56. The stock has a market cap of $279.71 million, a P/E ratio of 99.75 and a beta of 0.76.
Analyst Ratings Changes
Separately, Wall Street Zen raised shares of NANOPHASE TECHNOLOGIES to a "hold" rating in a report on Thursday, May 22nd.
Read Our Latest Stock Analysis on NANOPHASE TECHNOLOGIES
About NANOPHASE TECHNOLOGIES
(
Get Free Report)
Nanophase Technologies Corporation provides engineered materials, formulation development, and commercial manufacturing with an integrated family of technologies in the United States. It offers surface engineered zinc oxide and titanium dioxide for sunscreens and personal care products; fully formulated cosmetics, sun care, and skin care under the Solésence brand name; and advanced materials products, such as architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, medical diagnostics, and various surface finishing technologies applications.
Featured Articles
Before you consider Solesence, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solesence wasn't on the list.
While Solesence currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.